PTIX — Protagenic Therapeutics, Inc.\new

—
OTC · Health Care · Pharmaceuticals · CIK 1022899 ·
Last close
$0.45
Market Cap
$814.6K
52W High
$2.38
52W Low
$0.13
ADV30
1,360
Next earnings
—

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Dec 2025 0 — -925,103 2,210,769 4,431,101 2,212,646 6,823,789
Sep 2025 0 — -1,113,864 -869,496 5,002,847 2,722,451 9,703,412
Jun 2025 0 — -1,208,374 -5,057,523 6,488,200 4,096,189 10,462,212
Mar 2025 0 — -1,448,108 -1,440,005 988,650 872,960 1,076,979

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-4,140,350
Investing CF
$943,180
Financing CF
$4,510,070
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.45
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-9,113,856
Inventory
$1,074
Receivables
$41,523
ST Investments
—
EBIT TTM
$-8,305,871
Pretax Income TTM
$-5,156,255
Interest Exp TTM
$238,727
Analysts
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2024 0 -5,700,950 -5,525,344 1,955,913 942,759 1,013,154 -4,216,517
Dec 2023 0 -4,526,974 -5,000,497 4,323,369 655,252 3,668,117 -3,703,776
Dec 2022 0 -3,557,788 -3,555,505 8,037,420 1,119,862 6,917,558 -1,993,814
Dec 2021 0 -4,140,413 -4,522,934 11,059,923 1,117,968 9,941,955 -2,798,614

TTM Snapshot

Revenues TTM
$-8,103
NetIncome TTM
$1,844,366
OpCashFlow TTM
—
Assets (Latest)
$2,796,006
Forward EPS
$-0.58

Peers — same industry

TickerNameMarket CapLastDaily %
APVO Aptevo Therapeutics Inc. $834.5K $0.46 —
ATXI AVENUE THERAPEUTICS, INC. $922.6K $0.28 —
OGEN ORAGENICS INC $947.5K $0.21 —
SKVI SKINVISIBLE, INC. $972.7K $0.18 —
GOVX GeoVax Labs, Inc. $1.09M $2.01 —

News headlines (Yahoo Finance, 1h cache)

Protagenic Therapeutics Announces Private Placement of Up to $5 Million to Advance PT00114 into Its First U.S. Clinical Trial in Generalized Anxiety Disorder
2026-11-11 13:30 · Yahoo
Protagenic Therapeutics Appoints Industry Veteran Bill Nichols Jr. as President to Accelerate Advancement of First-in-Class TCAP Pathway Therapy PT00114
2026-04-23 12:15 · Yahoo
Protagenic Therapeutics Engages Floyd Regulatory Strategic Consulting as Regulatory Affairs Advisor and Danforth Health as Strategic Operations Partner
2026-05-19 12:15 · Yahoo
Protagenic Therapeutics Receives FDA Pre-IND Feedback Supporting New IND for PT00114 in Generalized Anxiety Disorder
2026-08-20 12:30 · Yahoo
Protagenic Therapeutics' Lead Candidate PT00114 Attenuated Chronic Stress Responses in a Well-Established Rodent Model
2026-06-30 12:30 · Yahoo
Protagenic Therapeutics Completes Phytanix Separation, Strengthens Balance Sheet and Repositions the Company Around PT00114
2026-03-17 12:00 · Yahoo
Protagenic Therapeutics Upgrades from OTC Pink to OTCQB Venture Market
2026-03-10 12:00 · Yahoo
Results from Phase 1 Multiple-Dose Study of PT00114
2025-12-09 13:46 · Yahoo
Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice
2025-11-27 08:45 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.